TCGA-ZF-AA56-01A-31R-A39I-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 8.508541393
- os_event
- true
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.560
- INTERFERON_ALPHA_RESPONSE+0.520
- INTERFERON_GAMMA_RESPONSE+0.520
- MTORC1_SIGNALING+0.500
- PROTEIN_SECRETION+0.490
- IL6_JAK_STAT3_SIGNALING+0.480
- INFLAMMATORY_RESPONSE+0.480
- TGF_BETA_SIGNALING+0.460
- MYC_TARGETS_V1+0.450
- TNFA_SIGNALING_VIA_NFKB+0.440
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.200
- SPERMATOGENESIS-0.160
- MYOGENESIS-0.090
- KRAS_SIGNALING_DN-0.050
- BILE_ACID_METABOLISM+0.000
- DNA_REPAIR+0.140
- APICAL_SURFACE+0.180
- MYC_TARGETS_V2+0.180
- UV_RESPONSE_UP+0.190
- PEROXISOME+0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 2DAB6792-F9AF-4565-BDD5-C9802F3132F4 | — | — | 0.951 |
| 2 | 443B59BB-0BFD-459A-896E-FA07AA6C3A45 | — | — | 0.948 |
| 3 | TCGA-CQ-5324-01A-01R-1686-07 | — | — | 0.946 |
| 4 | DB34442C-1882-495A-A2F0-2427116A1FAF | — | — | 0.935 |
| 5 | E9FC1686-028B-476C-B51B-4956213D874B | — | — | 0.935 |
| 6 | SRR934750 | — | — | 0.932 |
| 7 | TCGA-E7-A97P-01A-11R-A38B-07 | — | — | 0.931 |
| 8 | 7E198F8E-BBAA-419D-8986-359C109FBE74 | — | — | 0.931 |
| 9 | C6A60028-2402-4048-90DF-F2B3712FB530 | — | — | 0.931 |
| 10 | SRR934921 | — | — | 0.930 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 45 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.560 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.520 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.520 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.500 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.490 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.480 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.480 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.460 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.450 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.440 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.430 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.430 | Inavolisib | — uncovered |
| COMPLEMENT | 0.420 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.410 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.410 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.400 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.380 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.380 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.380 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.380 | Idelalisib | — uncovered |